Probi AB (publ) (PROB.ST)
SEK 347.0
(-0.29%)
SEK 347.0
(-0.29%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 181.31 Million SEK | 13.81% |
| 2022 | 159.32 Million SEK | -4.39% |
| 2021 | 166.62 Million SEK | 33.63% |
| 2020 | 124.69 Million SEK | -9.3% |
| 2019 | 137.48 Million SEK | -24.06% |
| 2018 | 181.03 Million SEK | -19.9% |
| 2017 | 225.99 Million SEK | -27.65% |
| 2016 | 312.37 Million SEK | 668.55% |
| 2015 | 40.64 Million SEK | 35.32% |
| 2014 | 30.03 Million SEK | 60.71% |
| 2013 | 18.69 Million SEK | 34.34% |
| 2012 | 13.91 Million SEK | 4.75% |
| 2011 | 13.28 Million SEK | 9.47% |
| 2010 | 12.13 Million SEK | 66.31% |
| 2009 | 7.29 Million SEK | -11.96% |
| 2008 | 8.28 Million SEK | -1.84% |
| 2007 | 8.44 Million SEK | -27.43% |
| 2006 | 11.63 Million SEK | 57.68% |
| 2005 | 7.37 Million SEK | -21.19% |
| 2004 | 9.36 Million SEK | -32.61% |
| 2003 | 13.89 Million SEK | 57.91% |
| 2002 | 8.79 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 155.86 Million SEK | -6.65% |
| 2024 Q2 | 166.96 Million SEK | 50.41% |
| 2024 Q1 | 111 Million SEK | -38.78% |
| 2023 Q3 | 138.47 Million SEK | -6.88% |
| 2023 FY | 181.31 Million SEK | 13.81% |
| 2023 Q2 | 148.7 Million SEK | -9.67% |
| 2023 Q1 | 164.62 Million SEK | 3.33% |
| 2023 Q4 | 181.31 Million SEK | 30.94% |
| 2022 Q3 | 154.37 Million SEK | -3.88% |
| 2022 Q2 | 160.6 Million SEK | 6.09% |
| 2022 FY | 159.32 Million SEK | -4.39% |
| 2022 Q4 | 159.32 Million SEK | 3.2% |
| 2022 Q1 | 151.38 Million SEK | -9.15% |
| 2021 Q3 | 130.39 Million SEK | -3.17% |
| 2021 Q2 | 134.66 Million SEK | -0.9% |
| 2021 Q1 | 135.88 Million SEK | 8.98% |
| 2021 Q4 | 166.62 Million SEK | 27.79% |
| 2021 FY | 166.62 Million SEK | 33.63% |
| 2020 Q3 | 107.19 Million SEK | -17.34% |
| 2020 Q1 | 132.62 Million SEK | -3.53% |
| 2020 FY | 124.69 Million SEK | -9.3% |
| 2020 Q2 | 129.67 Million SEK | -2.22% |
| 2020 Q4 | 124.69 Million SEK | 16.32% |
| 2019 Q4 | 137.48 Million SEK | -1.27% |
| 2019 FY | 137.48 Million SEK | -24.06% |
| 2019 Q3 | 139.25 Million SEK | -10.44% |
| 2019 Q2 | 155.48 Million SEK | -20.82% |
| 2019 Q1 | 196.37 Million SEK | 8.47% |
| 2018 FY | 181.03 Million SEK | -19.9% |
| 2018 Q4 | 181.03 Million SEK | -9.51% |
| 2018 Q3 | 200.05 Million SEK | -22.63% |
| 2018 Q2 | 258.56 Million SEK | 9.24% |
| 2018 Q1 | 236.69 Million SEK | 4.73% |
| 2017 Q4 | 225.99 Million SEK | -4.95% |
| 2017 Q1 | 300.94 Million SEK | -3.66% |
| 2017 Q3 | 237.77 Million SEK | -7.49% |
| 2017 Q2 | 257.02 Million SEK | -14.59% |
| 2017 FY | 225.99 Million SEK | -27.65% |
| 2016 FY | 312.37 Million SEK | 668.55% |
| 2016 Q1 | 40.89 Million SEK | 0.61% |
| 2016 Q3 | 861.67 Million SEK | 2249.63% |
| 2016 Q2 | 36.67 Million SEK | -10.32% |
| 2016 Q4 | 312.37 Million SEK | -63.75% |
| 2015 Q1 | 45.24 Million SEK | 50.64% |
| 2015 FY | 40.64 Million SEK | 35.32% |
| 2015 Q4 | 40.64 Million SEK | 14.35% |
| 2015 Q3 | 35.54 Million SEK | -9.98% |
| 2015 Q2 | 39.48 Million SEK | -12.74% |
| 2014 FY | 30.03 Million SEK | 60.71% |
| 2014 Q4 | 30.03 Million SEK | 12.85% |
| 2014 Q2 | 20.92 Million SEK | 24.13% |
| 2014 Q1 | 16.86 Million SEK | -9.79% |
| 2014 Q3 | 26.61 Million SEK | 27.17% |
| 2013 Q3 | 16.7 Million SEK | 5.68% |
| 2013 FY | 18.69 Million SEK | 34.34% |
| 2013 Q4 | 18.69 Million SEK | 11.92% |
| 2013 Q2 | 15.8 Million SEK | 8.9% |
| 2013 Q1 | 14.51 Million SEK | 4.31% |
| 2012 Q1 | 14.76 Million SEK | 11.17% |
| 2012 Q4 | 13.91 Million SEK | 15.46% |
| 2012 Q3 | 12.04 Million SEK | -6.75% |
| 2012 Q2 | 12.92 Million SEK | -12.48% |
| 2012 FY | 13.91 Million SEK | 4.75% |
| 2011 Q3 | 10.61 Million SEK | 1.39% |
| 2011 Q2 | 10.47 Million SEK | 0.93% |
| 2011 Q4 | 13.28 Million SEK | 25.07% |
| 2011 FY | 13.28 Million SEK | 9.47% |
| 2011 Q1 | 10.37 Million SEK | -14.47% |
| 2010 Q4 | 12.13 Million SEK | 0.0% |
| 2010 FY | 12.13 Million SEK | 66.31% |
| 2009 FY | 7.29 Million SEK | -11.96% |
| 2008 FY | 8.28 Million SEK | -1.84% |
| 2007 FY | 8.44 Million SEK | -27.43% |
| 2006 FY | 11.63 Million SEK | 57.68% |
| 2005 FY | 7.37 Million SEK | -21.19% |
| 2004 FY | 9.36 Million SEK | -32.61% |
| 2003 FY | 13.89 Million SEK | 57.91% |
| 2002 FY | 8.79 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AcuCort AB | 10.97 Million SEK | -1552.1% |
| AlzeCure Pharma AB (publ) | 8.22 Million SEK | -2103.938% |
| BioGaia AB (publ) | 302.84 Million SEK | 40.128% |
| Enzymatica AB (publ) | 49.3 Million SEK | -267.77% |
| Enorama Pharma AB (publ) | 14.84 Million SEK | -1121.243% |
| Gabather AB (publ) | 6.87 Million SEK | -2536.202% |
| Klaria Pharma Holding AB (publ.) | 31.98 Million SEK | -466.867% |
| Moberg Pharma AB (publ) | 24 Million SEK | -655.271% |
| Nanexa AB (publ) | 36.42 Million SEK | -397.757% |
| Newbury Pharmaceuticals AB (publ) | 38.95 Million SEK | -365.467% |
| ODI Pharma AB | 10.05 Million SEK | -1702.783% |
| Orexo AB (publ) | 727.7 Million SEK | 75.083% |
| Swedencare AB (publ) | 2.31 Billion SEK | 92.169% |
| Swedish Orphan Biovitrum AB (publ) | 40.16 Billion SEK | 99.549% |
| Toleranzia AB | 6.9 Million SEK | -2524.374% |
| Vivesto AB | 30.45 Million SEK | -495.422% |